Biotech

All Articles

Analysts examine Avidity's DMD win, exposing nuances in records

.Avidity Biosciences impressed clients along with phase 1/2 data in Duchenne muscle dystrophy (DMD) ...

Actinogen's cortisol blocker fails period 2 depression study

.Actinogen Medical's cortisol blocker has actually missed the key endpoint of a stage 2 research stu...

Bivictrix makes a decision going private only method to take ADC right into clinic

.Antibody-drug conjugates (ADCs) have been at the center of a lot of a billion-dollar biobuck licens...

TPG bests up funds to $580M for expenditures around life scientific researches

.Possession manager TPG, which has actually sustained biotechs like Sionna Therapies and also Santa ...

Merck quits period 3 TIGIT trial in lung cancer cells for futility

.Merck &amp Co.'s TIGIT plan has actually experienced another obstacle. Months after shuttering a pe...

After a tough year, Exscientia folds up into Recursion

.After a year determined by pipe hairstyles, the departure of its chief executive officer as well as...

Cullinan, after $25M bargain, hands back bispecific to Harbour

.Cullinan Therapeutics was impressed enough with Harbour BioMed's bispecific invulnerable reactor th...

A more detailed examine Strong Biotech's Strong 15

.In this week's incident of "The Best Pipe," our company're diving right into Ferocious Biotech's ye...

Lilly deals with stage 2 breakdown of tau-targeting med

.The confetti is still flying from Eli Lilly's celebration commemorating the commendation of Alzheim...

Biogen CMO Maha Radhakrishnan signs up with Sofinnova-- Chutes &amp Ladders

.Invite to recently's Chutes &amp Ladders, our summary of notable management hirings, firings as wel...